Search
Search Results
-
Control of the antitumour activity and specificity of CAR T cells via organic adapters covalently tethering the CAR to tumour cells
On-target off-tumour toxicity limits the anticancer applicability of chimaeric antigen receptor (CAR) T cells. Here we show that the tumour-targeting...
-
Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors
The application of chimeric antigen receptor (CAR) T cells in the management of hematological malignancies has emerged as a noteworthy therapeutic...
-
-
Revolutionizing cancer treatment: a comprehensive review of CAR-T cell therapy
Chimeric antigen receptor (CAR)-T cell therapy is a promising new treatment for cancer that involves genetically modifying a patient’s T-cells to...
-
CAR-T Cell Therapy in Pancreatic and Biliary Tract Cancers: An Updated Review of Clinical Trials
BackgroundPancreatic and biliary tract cancers are digestive system tumors with dismal prognosis and limited treatment options. The effectiveness of...
-
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
Therapies with genetically modified T cells that express chimeric antigen receptors (CARs) specific for CD19 or B cell maturation antigen (BCMA) are...
-
Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility
Cancer immunotherapies utilizing genetically engineered T cells have emerged as powerful personalized therapeutic agents showing dramatic preclinical...
-
Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment
The past decade has witnessed ongoing progress in immune therapy to ameliorate human health. As an emerging technique, chimeric antigen receptor...
-
CAR T cells: engineered immune cells to treat brain cancers and beyond
Malignant brain tumors rank among the most challenging type of malignancies to manage. The current treatment protocol commonly entails surgery...
-
Immunotherapy and immunoengineering for breast cancer; a comprehensive insight into CAR-T cell therapy advancements, challenges and prospects
BackgroundBreast cancer (BC) is a highly prevalent solid cancer with a high-rise infiltration of immune cells, turning it into a significant...
-
Nano-optogenetic engineering of CAR T cells for precision immunotherapy with enhanced safety
Chimeric antigen receptor (CAR) T cell-based immunotherapy, approved by the US Food and Drug Administration, has shown curative potential in patients...
-
Biomarkers as targets for CAR-T/NK cell therapy in AML
The most common kind of acute leukemia in adults is acute myeloid leukemia (AML), which is often treated with induction chemotherapy regimens...
-
Recent Innovative Approaches to Intensify the Efficacy and Safety of CAR-T Cell Therapy in Cancers
In recent decades, the advent of chimeric antigen receptor (CAR)-T cell therapy has revolutionized cancer treatment, especially hematological...
-
CAR-T Cells and Other Related Technologies
Chimeric antigen receptor (CAR) cells (including T lymphocytes and natural killer cells) are cells modified to express a transmembrane protein that...
-
Hurdles to breakthrough in CAR T cell therapy of solid tumors
Autologous T cells genetically engineered to express chimeric antigen receptor (CAR) have shown promising outcomes and emerged as a new curative...
-
-
Engineering switchable and programmable universal CARs for CAR T therapy
A traditional chimeric antigen receptor (CAR) has a fixed design, and one type of CAR T cells can only target one antigen epitope. This rigid design...
-
Control of the activity of CAR-T cells within tumours via focused ultrasound
Focused ultrasound can deliver energy safely and non-invasively into tissues at depths of centimetres. Here we show that the genetics and cellular...
-
Remote control of cellular immunotherapy
Chimeric antigen receptor (CAR) T cell immunotherapy is emerging as a powerful tool for cancer treatment. However, the clinical application of CAR T...
-
Combination of CRISPR/Cas9 System and CAR-T Cell Therapy: A New Era for Refractory and Relapsed Hematological Malignancies
Chimeric antigen receptor T (CAR-T) cell therapy is the novel treatment strategy for hematological malignancies such as acute lymphoblastic leukemia...